Archives

The launching in Europe of a trial testing a new anti-HIV molecule causes the indignation of some organizations, who denounce the risk of a «loss of options» for the patients. Convinced that they are doing the right thing, the trial promoters, Schering-Plough laboratory, first refused all negotiations, and then offered a disappointing conciliation.

The strategy pursued by drug giant Pfizer for the development of its new anti-HIV product (an inhibiter of the CCR5 receptor) is putting at risk the health of hundreds of treatment-naïve patients with low CD4 count and high viral load [Le TRT-5 and EATG have had similar problems with trial P03802, aiming to evaluate Schering Plough anti-CCR5 compound, SCH 690. The Journal of Health Democracy has published [an article on this issue ]]. TRT5 [[TRT-5 (Traitements et Recherche Thérapeutique) is an inter-collaborative group consisting of Actions Traitements, Act Up-Paris, Aides, Arcat, , Dessine-Moi Un Mouton, Nova Dona, Sida Info Service, Sol En Si, and is also a close collaborator of European Aids Treatment Group (EATG).]], the inter-collaborative group for French HIV treatment advocates, denounces this unethical practice and alerts the various authorities concerned by this trial.